Business
Protalix BioTherapeutics Letter to Stockholders
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced the following update from President and Chief Executive Officer, Dror Bashan, to its stockholders.
About this update from Protalix Biotherapeutics, Inc. (de)
[{"type":"text","content":"CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced the following update from President and Chief Executive Officer, Dror Bashan, to its stockholders.","length":388,"tagName":"p"},{"type":"image","alt":"Protalix Biotherapeutics Logo","displaySize":"","headline":null,"caption":"Protalix Biotherapeutics Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":121,"url":"https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JqTp0X7VmxnrsXQUFDueUg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f2174d5c59bc5e34e9e5ea6a94c7eeba","width":400,"height":121}}},{"type":"text","content":"Dear Protalix Stockholders,","length":27,"tagName":"p"},{"type":"text","content":"As we look forward to 2026, we remain focused on building with our partners a growing, profitable business and an innovative pipeline for patients with high-need rare diseases.","length":176,"tagName":"p"},{"type":"text","content":"A core element of this plan is our advancement of PRX-115 for patients with uncontrolled gout. Clinical data from our Phase 1 trial demonstrate that PRX-115 provides a rapid and durable urate-lowering effect with a favorable tolerability profile, supporting its potential as a meaningful differentiated treatment option. Epidemiologic analyses confirm gout prevalence continues to rise worldwide, with U.S. rates increasing significantly over the last two decades.1,2 Despite available therapies, a large proportion of patients remain uncontrolled due to treatment limitations and poor adherence.3,4 Uncontrolled gout is a high–need, high–value indication and PRX-115 has the potential to deliver a differentiated clinical profile with rapid onset and durable urate control. PRX-115 emerges from our internal pipeline as a possible third molecule for commercialization.","length":874,"tagName":"p"},{"type":"text","content":"In parallel, we are sharpening our strategic focus on rare kidney diseases to build a renal pipeline through innovation and partnerships — starting wit...